Filtered By:
Drug: Coumadin

This page shows you your search results in order of relevance. This is page number 16.

Order by Relevance | Date

Total 3661 results found since Jan 2013.

Prevalence, Mechanisms, and Management of Ischemic Stroke in Heart Failure Patients
Semin Neurol DOI: 10.1055/s-0041-1726329Heart failure (HF) and stroke, two of the major causes of death worldwide, are closely associated. Although atrial fibrillation (AF), which occurs in more than half of patients with HF, is a major risk factor for stroke, there is a great deal of evidence that HF itself increases the risk of stroke independent of AF. The main mechanism of stroke appears to be thromboembolism. However, previous studies have failed to demonstrate the benefit of warfarin in patients with HF without AF, as the benefit of stroke prevention was counteracted by the increased incidence of major bleeding. Rece...
Source: Seminars in Neurology - April 13, 2021 Category: Neurology Authors: Seol, Hyeyoung Kim, Jong S. Tags: Review Article Source Type: research

Adherence to oral anticoagulation in ischemic stroke patients with atrial fibrillation
CONCLUSIONS: Adherence was poor in half of AF patients who survived an ischaemic stroke. Independent patient-related factors, rather than composite scores, were associated with poor adherence in these patients.KEY MESSAGESAdherence was poor in half of the atrial fibrillation patients who survived an ischaemic stroke.Independent patient-related factors rather than composite scores were associated with poor adherence.The findings support the importance of recognising adherence support as a crucial part of holistic patient care recommended by recent AF guideline.PMID:34498537 | DOI:10.1080/07853890.2021.1968031
Source: Annals of Medicine - September 9, 2021 Category: Internal Medicine Authors: Paula Tiili Ioannis Leventis Janne Kinnunen Ida Svedjeb äck Mika Lehto Efstathia Karagkiozi Dimitrios Sagris George Ntaios Jukka Putaala Source Type: research

Comparison of Antiplatelet and Antithrombotic Therapy for Secondary Prevention of Ischemic Stroke in Patients With Peripheral Artery Disease.
Conclusions: Cilostazol and clopidogrel were more effective in preventing recurrent ischemic stroke without increased hemorrhagic events than aspirin in patients with PAD. PMID: 23269006 [PubMed - as supplied by publisher]
Source: Circulation Journal - December 26, 2012 Category: Cardiology Authors: Lee WH, Chu CY, Hsu PC, Su HM, Lin TH, Voon WC, Lai WT, Sheu SH Tags: Circ J Source Type: research

Beneficial effects of stroke-unit care in stroke patients with atrial fibrillation.
Conclusion: SU care improved the detection of AF and the rate of anticoagulation consideration in acute stroke patients. Our findings support the benefits of continuous cardiac monitoring in the SU for stroke patients. PMID: 23364960 [PubMed - in process]
Source: Yonsei Medical Journal - February 4, 2013 Category: Universities & Medical Training Authors: Choi HY, Seo JH, Yang JH, Kim YD, Jung YH, Cho HJ, Nam HS, Heo JH Tags: Yonsei Med J Source Type: research

Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation Analysis From the ROCKET AF Trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)
ConclusionsIn atrial fibrillation patients who temporarily or permanently discontinued anticoagulation, the risk of stroke or non-CNS embolism was similar with rivaroxaban or warfarin. An increased risk of stroke and non-CNS embolism was observed in rivaroxaban-treated patients compared with warfarin-treated patients after the end of the study, underscoring the importance of therapeutic anticoagulation coverage during such a transition.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - February 4, 2013 Category: Cardiology Source Type: research

Systematic review and meta-analysis looks at risk factors for stroke in patients taking warfarin for AF
Source: Stroke Area: News The results of a systematic review and meta-analysis seeking to identify the risk factors that contribute to stroke risk in patients with atrial fibrillation (AF) who are taking an oral anticoagulant (OAC) have been published early online in the journal 'Stroke'.   The authors note that although OACs reduce the risks of stroke and mortality in patients with AF, some patients taking them will still sustain stroke.  They performed a systematic review to identify contemporary randomised clinical trials investigating OACs in patients with AF, and then performed a meta-analysis of recent...
Source: NeLM - Cardiovascular Medicine - March 25, 2013 Category: Cardiology Source Type: news

Review of Economics and Cost-Effectiveness Analyses of Anticoagulant Therapy for Stroke Prevention in Atrial Fibrillation in the US.
CONCLUSIONS: This review identified several areas of uncertainty regarding the economic benefit of anticoagulants. The generalizability of cost-effectiveness results of anticoagulant therapy in AF based on clinical trial data must be confirmed by comparative effectiveness research conducted in the real-world setting. PMID: 23606551 [PubMed - in process]
Source: The Annals of Pharmacotherapy - May 1, 2013 Category: Drugs & Pharmacology Authors: von Schéele B, Fernandez M, Hogue SL, Kwong WJ Tags: Ann Pharmacother Source Type: research

N-Terminal Pro–B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation)
This study sought to assess the prognostic value of N-terminal pro–B-type natriuretic peptide (NT-proBNP) in patients with atrial fibrillation (AF) enrolled in the ARISTOTLE (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation) trial, and the treatment effect of apixaban according to NT-proBNP levels.Background: Natriuretic peptides are associated with mortality and cardiovascular events in several cardiac diseases.Methods: In the ARISTOTLE trial, 18,201 patients with AF were randomized to apixaban or warfarin. Plasma samples at randomization were available from 14,892 patients. The association bet...
Source: Journal of the American College of Cardiology - April 5, 2013 Category: Cardiology Authors: Ziad Hijazi, Lars Wallentin, Agneta Siegbahn, Ulrika Andersson, Christina Christersson, Justin Ezekowitz, Bernard J. Gersh, Michael Hanna, Stefan Hohnloser, John Horowitz, Kurt Huber, Elaine M. Hylek, Renato D. Lopes, John J.V. McMurray, Christopher B. Gr Tags: Atrial Fibrillation Source Type: research

N-Terminal Pro–B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial Fibrillation Insights From the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation)
This study sought to assess the prognostic value of N-terminal pro–B-type natriuretic peptide (NT-proBNP) in patients with atrial fibrillation (AF) enrolled in the ARISTOTLE (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation) trial, and the treatment effect of apixaban according to NT-proBNP levels.BackgroundNatriuretic peptides are associated with mortality and cardiovascular events in several cardiac diseases.MethodsIn the ARISTOTLE trial, 18,201 patients with AF were randomized to apixaban or warfarin. Plasma samples at randomization were available from 14,892 patients. The association between...
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - May 30, 2013 Category: Cardiology Source Type: research

Apixaban: A New Factor Xa Inhibitor for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation
Atrial fibrillation (AF) is an independent risk factor for ischemic stroke occurrence, severity, recurrence, and mortality. Anticoagulation therapy for the prevention of thromboembolism is critical in patients with AF who are at risk of stroke. Warfarin has been an efficacious anticoagulant for this purpose, but its use has been limited by frequent laboratory monitoring, drug interactions, unpredictable individual response, delayed onset of action, and bleeding. Apixaban is the second oral direct selective factor Xa inhibitor approved for the prevention of stroke/systemic embolism in patients with nonvalvular AF. It was si...
Source: Cardiology in Review - June 6, 2013 Category: Cardiology Tags: New Therapy Update Source Type: research

Stroke prevention in atrial fibrillation—An Asian stroke perspective
Despite relatively lower prevalence of atrial fibrillation (AF) in Asians (~1%) than in Caucasians (~2%), Asia has a much higher overall disease burden because of its proportionally larger aged population. For example, on the basis of reported age-adjusted prevalence rates and projected population figures in China, there will be an estimated 5.2 million men and 3.1 million women with AF older than 60 years by year 2050. Stroke is a disabling complication of AF that is of increasing cause for concern in Asians patients. Implementing consensus expert recommendations for managing stroke risk in patients with AF can considerab...
Source: Heart Rhythm - March 18, 2013 Category: Cardiology Authors: Hung-Fat Tse, Yong- Jun Wang, Moheeb Ahmed Ai-Abdullah, Annette B. Pizarro-Borromeo, Chern-En Chiang, Rungroj Krittayaphong, Balbir Singh, Amit Vora, Chun-Xue Wang, Mohammad Zubaid, Andreas Clemens, Paul Lim, Dayi Hu Tags: Contemporary Review--Associate Editor: Sami Viskin Source Type: research

Stroke or Transient Ischemic Attack in Patients with Transvenous Pacemaker or Defibrillator and Echocardiographically Detected Patent Foramen Ovale.
CONCLUSIONS: In patients with endocardial leads, the presence of a PFO on routine echocardiography is associated with a substantially increased risk of embolic stroke/TIA. This finding suggests a role of screening for PFOs in patients who require CIEDs, if detected, PFO closure, anticoagulation, or non-vascular lead placement may be considered. PMID: 23946264 [PubMed - as supplied by publisher]
Source: Circulation - August 14, 2013 Category: Cardiology Authors: Desimone CV, Friedman PA, Noheria A, Patel NA, Desimone DC, Bdeir S, Aakre CA, Vaidya VR, Slusser JP, Hodge DO, Ackerman MJ, Rabinstein AA, Asirvatham SJ Tags: Circulation Source Type: research

Safety of intravenous thrombolysis for ischemic stroke in patients treated with warfarin
ObjectiveControversy surrounds the safety of intravenous (IV) tissue plasminogen activator (tPA) in ischemic stroke patients treated with warfarin. The European tPA license precludes its use in anticoagulated patients altogether. American guidelines accept IV tPA use with an international normalized ratio (INR) ≤ 1.7. The influence of warfarin on symptomatic intracerebral hemorrhage (SICH), arterial recanalization, and long‐term functional outcome in stroke thrombolysis remains unclear. MethodsWe analyzed data from 45,074 patients treated with IV tPA enrolled in the Safe Implementation of Thrombolysis in Stroke (SITS) ...
Source: Annals of Neurology - September 4, 2013 Category: Neurology Authors: Michael V. Mazya, Kennedy R. Lees, Romesh Markus, Risto O. Roine, Raymond C. S. Seet, Nils Wahlgren, Niaz Ahmed, Tags: Original Article Source Type: research

Selection of Warfarin or One of the New Oral Antithrombotic Agents for Long-Term Prevention of Stroke among Persons with Atrial Fibrillation
Opinion statement Atrial fibrillation (AF) is the most common sustained cardiac rhythm disorder, which can potentially increases the risk of stroke by five-fold, thus, resulting in high public healthcare burden. Stroke prevention is vital in the management of AF patients. Vitamin K antagonists (VKA, eg, warfarin) have been the mainstay treatment to prevent ischemic stroke and systemic thromboembolism in AF patients for several decades. Despite the efficacy of warfarin, its limitations have recently driven the advent of some new antithrombotic agents, the non-VKA oral anticoagulant (NOACs, including dabigatran, ri...
Source: Current Treatment Options in Neurology - February 11, 2015 Category: Neurology Source Type: research

Stroke prevention in atrial fibrillation: an update on current management strategies.
Authors: Hall T, Stanton T, Wang WY, Ng AC Abstract Stroke attributed to atrial fibrillation (AF) confers significant morbidity and mortality. In the past, warfarin has been the only successful stroke prevention agent available. However, it is often underutilized due to its well-known limitations, leaving many patients without adequate stroke protection. The last decade has seen significant strides forward in the field of anticoagulation for AF. The development of several novel oral anticoagulants that have superior efficacy, improved safety profile and fixed doses without the need for regular monitoring make them ...
Source: Panminerva Medica - June 4, 2015 Category: Journals (General) Tags: Panminerva Med Source Type: research